Overview of the Market:
The Asia-Pacific nuclear medicine diagnostic market is estimated at $2.01 billion in 2018 and is poised to reach $3.86 billion by 2023, at a CAGR of 13.9%. Nuclear medicine is a branch of medicine that uses radiation to deliver information about the functioning of a person's specific organs or to treat a disease. In most of the cases, the information helps to assist the physicians to make a quick and accurate diagnosis of the patient's illness.
SPECT imaging is the most conventional modality for nuclear medicine applications such as nuclear cardiology procedures. However, the trend is soon going to see a down turn owing to the shortage of molybdenum-99 isotope which in turn will lead to deficiency of Technetium-99, which is the by-product of molybdenum. Therefore, PET imaging products include hybrid PET-CT scanners are anticipated to account for a potentially hefty market share in the near future.
The emerging market tendency will be a fusion of nuclear imaging with different diagnostic imaging products such as SPECT/CT, PET/CT and MRI/PET. This provides full range of imaging scans through the same unit and at the same time. PET market is expected to witness fastest growth compared to SPECT imaging as it delivers higher resolution images and the technetium-99m is forcing industry to look for alternative diagnostic procedures
Increasing usage of SPECT and PET in medical diagnostics, rising awareness among people about radiopharmaceuticals, and ready availability of radiopharmaceuticals are some of the factors fuelling the growth of the market.However, shorter half- life of radioisotopes, regulatory guidelines, high capital investment and reimbursement issues are acting as hurdles for the nuclear medicine market growth.
The Nuclear Medicine Market is segmented into two major segments SPECT (Technetium-99m (TC-99m), Iodine (I-123) Thallium-201 (TL-201) and others) and PET (Rubidium-82 (RB-82), Fluorine-18, and others). By application,the market is categorized into SPECT (lymphoma, cardiology,neurology,thyroid and others) and PET(cardiology,oncology, neurology and others).
Geographical Analysis:
Furthermore, on the basis of geography, the market is divided into India, China, Japan and South Korea.
Key Players in this Market:
Some of the key players influencing the Asia-Pacific nuclear medicine market are Cardinal Health, Inc., Bracco Imaging S.p.A,GE Healthcare,Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc.,Advanced Accelerator Applications S.A., IBA Molecular Imaging, and Mallinckrodt plc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Type
5.1.1 SPECT
5.1.1.1 Technetium-99m
5.1.1.2 Thallium-201
5.1.1.3 Gallium-67
5.1.1.4 Iodine-23
5.1.1.5 Others
5.1.2 PET
5.1.2.1 Fluorine-18
5.1.2.2 Rubidium-82
5.1.2.3 Others
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cardinal Health Inc.
8.3 Bracco Imaging S.p.A
8.4 Eczacibasi-Monrol Nuclear Products
8.5 Nordion, Inc.
8.6 Bayer Healthcare
8.7 Lantheus Medical Imaging, Inc.
8.8 Advanced Accelerator Applications S.A.
8.9 IBA Molecular Imaging
8.10 Mallinckrodt plc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
